ARMP
Armata Pharmaceuticals Inc
3.30$
-9.8%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +10.0% | -42.2% | -38.8% | +6.7% | +114.1% | +55.3% | +76.6% | +54.6% | -8.8% | -12.1% | -11.1% | |
| – | +42.7% | -36.6% | -15.3% | +56.1% | -20.8% | +63.0% | +38.3% | +80.4% | -29.2% | -41.0% | -5.7% | |
| – | +42.4% | -39.1% | -10.1% | +58.9% | -26.0% | +59.9% | +6.6% | +44.4% | -8.9% | -31.3% | -6.5% | |
| – | +42.4% | -39.1% | -10.1% | +58.9% | -26.0% | +59.9% | +6.6% | +44.4% | -8.9% | -31.3% | -6.5% | |
| – | +25.0% | -80.0% | – | – | – | – | +432.8% | +185.4% | -60.6% | -77.9% | -36.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -5.2% | +256.5% | -15.0% | +29.7% | +204.6% | -82.7% | +62.9% | – | – | – | |
| – | +0.0% | -100.0% | – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -0.2% | -15.8% | -54.2% | -39.7% | +244.6% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -25.4% | -54.9% | -59.8% | +0.2% | +218.1% | +90.3% | +114.8% | +61.8% | +81.7% | +3.1% | +119.8% | |
| – | +27.7% | +50.1% | -45.0% | +30.7% | +89.7% | +37.4% | -28.2% | +416.7% | -33.8% | +193.1% | -81.5% | |
| – | – | – | -100.0% | – | – | +73.8% | -33.6% | +1,027.3% | -44.3% | +357.6% | -89.5% | |
| – | -10.5% | +1.1% | -45.3% | +26.1% | -25.0% | +74.8% | +19.0% | +47.5% | -5.5% | -51.7% | +20.2% | |
| – | – | – | – | – | – | – | – | – | – | -32.6% | +363.5% | |
| – | +269.9% | -23.5% | -20.5% | +9.6% | +72.2% | +29.2% | +34.7% | +42.1% | -188.9% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -16.4% | -81.8% | +6,392.7% | -27.2% | +2,255.2% | +109.7% | +46.8% | +42.3% | +5.2% | +0.2% | +0.2% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.